Immune Cell Therapies and Immune Cell Engineering

Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated immunosuppression induced by CAR-T treatment
Dan Liu, Xiyue Xu, Yulian Dai, Xuan Zhao, Shunshun Bao, Wen Ma, Li Zha, Shuci Liu, Yuchen Liu, Junnian Zheng, Ming Shi

Journal for ImmunoTherapy of Cancer Jan 2021, 9 (1) e001466; DOI: 10.1136/jitc-2020-001466
Deletion of Cbl-b inhibits CD8⁺ T-cell exhaustion and promotes CAR T-cell function
Jitendra Kumar, Ritesh Kumar, Amir Kumar Singh, Elviche L Tsakem, Mahesh Kathania, Matthew J Riese, Arianne L Theiss, Marco L Davila, K Venuprasad

Journal for ImmunoTherapy of Cancer Jan 2021, 9 (1) e001688; DOI: 10.1136/jitc-2020-001688
CD8⁺ chimeric antigen receptor T cells manufactured in absence of CD4⁺ cells exhibit hypofunctional phenotype
Sang Yun Lee, Dong Hoon Lee, Wei Sun, Francisco Cervantes-Contreras, Ryan S Basom, Feinan Wu, Si Liu, Richa Rai, Hamid R Mirzaei, Shyril O’Steen, Damian J Green, Mazyar Shadman, Brian G Till

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (11) e007803; DOI: 10.1136/jitc-2023-007803
Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer
Els M E Verdegaal, Saskia J Santegoets, Marij J P Welters, Linda de Bruin, Marten Visser, Caroline E van der Minne, Pita M de Kok, Nikki M Loof, Sanne Boekestijn, Inge Roozen, Inge M Westra, Pauline Meij, Sjoerd H Van der Burg, Judith R Kroep

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (11) e007697; DOI: 10.1136/jitc-2023-007697
Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy
Michael Winkelmann, Viktoria Blumenberg, Kai Rejeski, Christina Quell, Veit Bücklein, Maria Ingenerf, Marcus Unterrainer, Christian Schmidt, Franziska J Dekorsy, Peter Bartenstein, Jens Ricke, Michael von Bergwelt-Baildon, Marion Subklewe, Wolfgang G Kunz

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e006659; DOI: 10.1136/jitc-2022-006659
Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy
Tsung-Yi Lin, Jeong A Park, Alan Long, Hong-Fen Guo, Nai-Kong V Cheung

Journal for ImmunoTherapy of Cancer Sep 2021, 9 (9) e003114; DOI: 10.1136/jitc-2021-003114
Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells
Justin T Huckaby, Elisa Landoni, Timothy M Jacobs, Barbara Savoldo, Gianpietro Dotti, Samuel K Lai

Journal for ImmunoTherapy of Cancer Sep 2021, 9 (9) e002737; DOI: 10.1136/jitc-2021-002737
Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design
Haiying Qin, Lila Yang, John A Chukinas, Nirali N Shah, Samiksha Tarun, Marie Pouzolles, Christopher D Chien, Lisa M Niswander, Anthony R Welch, Naomi A Taylor, Sarah K Tasian, Terry J Fry

Journal for ImmunoTherapy of Cancer Sep 2021, 9 (9) e003149; DOI: 10.1136/jitc-2021-003149
Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors
Konstantinos Lontos, Yiyang Wang, Supriya K Joshi, Andrew T Frisch, McLane J Watson, Alok Kumar, Ashley V Menk, Yupeng Wang, Rachel Cumberland, Jason Lohmueller, Esteban Carrizosa, Benjamin Boyerinas, Greg M Delgoffe

Journal for ImmunoTherapy of Cancer Mar 2023, 11 (3) e006522; DOI: 10.1136/jitc-2022-006522
CD47 expression is critical for CAR T-cell survival in vivo
Alex N Beckett, Peter Chockley, Shondra M Pruett-Miller, Phuong Nguyen, Peter Vogel, Heather Sheppard, Giedre Krenciute, Stephen Gottschalk, Christopher DeRenzo

Journal for ImmunoTherapy of Cancer Mar 2023, 11 (3) e005857; DOI: 10.1136/jitc-2022-005857

Main menu

Immune Cell Therapies and Immune Cell Engineering

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Immune Cell Therapies and Immune Cell Engineering

Pages